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Abstract 
Introduction: There is an increasing awareness to integrate patient blood management (PBM) within 
routine surgical care in order to improve patient outcome. Although often standard in orthopedic and 
cardiac surgery, limited information about the use and implementation of PBM in colorectal cancer 
surgery is available. This is curious, as preoperative anemia, associated with increased morbidity and 
mortality, is highly prevalent in colorectal cancer patients. The present study therefore aimed to assess 
the current preoperative blood management strategies in the Netherlands, and to identify preferences 
of different physicians in the treatment of preoperative anemia in this particular patient group. 
Methods: An online electronic survey was developed and sent to all surgeons of the Dutch Taskforce 
Coloproctology (177 in total). In addition, for each hospital in which surgery for colorectal cancer 
surgery is performed (75 in total), the survey was sent to one gastroenterologist and one 
anesthesiologist. Analyses of survey data were performed using descriptive statistics 
Results: A total of 192 physicians responded to the survey (overall response rate 58.7%). In 73 
hospitals (97.3%) the survey was conducted by at least one physician, and in more detail, in 21 
hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist and a 
gastroenterologist. Regarding the management of  a mild to moderate preoperative anemia, no clear 
policy was reported in half of the hospitals (49.3%). Treatment of  a mild to moderate preoperative 
anemia was initiated by the gastroenterologist, 14.7%; surgeon, 20.0%; colon care nurse, 5.3%; 
hematologist, 2.7%; anesthesiologist, 2.7%. In 38.7% of the hospitals, iron parameters were measured 
during screening for colorectal cancer. In addition, in only 13.3% of the hospitals, iron parameters 
were measured by the anesthesiologist during preoperative assessment. The most important objective 
for the treatment of anemia was ‘the prevention of blood transfusions because of their association with 
impaired long-term tumor prognosis’. Furthermore, the severity of anemia was considered as the most 
important factor to treat anemia (98% of all respondents). 
Conclusion: The present study shows a distinct variability in preoperative blood management 
practices in colorectal cancer care. Strikingly, this variability which was not only seen among, but also 
within Dutch hospitals, was demonstrated by variable responses from gastroenterologists, surgeons 
and anesthesiologists from the same institution. As a result, the present study clearly demonstrates 
the lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting 
in a suboptimal preoperative blood management strategy.  
Introduction 
Preoperative anemia in colorectal cancer patients is associated with an increased risk of short-term 
mortality and morbidity, and a decrease in long-term tumor survival.1, 2 Iron deficiency is the principal 
cause of preoperative anemia and is reported in almost 50% of preoperative colorectal cancer 
patients.3, 4 Transfusion, in earlier days the default therapy to correct this anemia, however, is also 
known to be associated with increased morbidity and mortality, as already demonstrated by Busch et 
al. in 1993.5-9 This has resulted in alternative approaches to treat preoperative anemia, which are 
collectively known as patient blood management (PBM). 
 
PBM refers to ‘the timely application of evidence based medical and surgical concepts designed to 
maintain hemoglobin concentration, optimize hemostasis and minimize blood loss in an effort to 
improve patient outcome’. It has been developed to promote strategies to reduce or avoid the need of 
blood transfusion, and therefore questions blood transfusion as the primary treatment strategy of 
anemia. PBM is a continuous process, initiated early in the preoperative period and continued intra- 
and postoperatively. Importantly, and by definition, PBM requires a multimodal and multidisciplinary 
strategy, and should at least involve surgeons, anesthesiologists, gastroenterologists, hematologists 
and nurses.10 
 
The increasing awareness to integrate PBM within routine surgical care resulted in numerous ongoing 
trials studying the optimal blood management strategy in all types of surgery.11-13 To date, studies on 
the use and implementation of these PBM strategies are mostly limited to orthopedic and cardiac 
surgery.10, 14 Despite the high prevalence of preoperative anemia, associated with increased morbidity 
and mortality, limited information about the use and implementation of PBM strategies in colorectal 
cancer care is available. A review by Munoz et al. represents a clear exception to this.15 In this review, 
the prevalence and consequences of anemia are discussed and a pragmatic approach to the 
treatment of perioperative anemia in colorectal cancer patients is presented.  
 
With the present study, we focused on the preoperative assessment and treatment of anemia in 
colorectal cancer patients and aimed to 1) assess the current preoperative blood management 
strategies in the Netherlands, 2) identify preferences of different physicians (surgeons, 
anesthesiologists and gastroenterologists) in the treatment of preoperative anemia, and 3) evaluate 
physicians’ general knowledge of blood management issues.  
 
Methods 
Study design 
To accomplish our objectives, an online electronic survey was developed. The survey included three 
topics: 1) questions on the current preoperative blood management practice in colorectal cancer 
patients (measurement of iron parameters and treatment of preoperative anemia), 2) questions on 
physicians’ preferences in treatment of preoperative anemia (best treatment of preoperative anemia 
and the goal of treatment) and 3) questions to test physicians’ knowledge of blood management 
issues. The survey questions were made by the research fellow (MJW) and two hematologists (MS 
and JJZ), and were subsequently tested at two sites (Department of Surgery Reinier de Graaf 
Hospital, and Department of Anesthesiology Albert Schweitzer Hospital). The eventual revised 
questionnaire was sent by e-mail to the eligible participants. The online survey tool SurveyMonkey 
was used to conduct the survey. 
 
Study population 
After obtaining the mailing list, the survey was first sent to all surgeons of the Dutch Taskforce 
ColoProctology (Werkgroep Coloprotocologie) in May 2017. Subsequent e-mail reminders were sent 
out in July and September 2017. In addition, for each hospital in which surgery for colorectal cancer is 
performed (75 in total), the survey was sent to one gastroenterologist and one anesthesiologist, all 
involved in colorectal cancer care and usually the head of department. For this purpose, the survey 
was slightly modified to suit the clinical situation of the gastroenterologist and anesthesiologist. The 
first invitation was sent in June 2017 and subsequent e-mail reminders were sent out in July and 
September 2017. The participation period closed in October 2017.  
Removal of undeliverable e-mails from the mailing list, as well as retired or relocated surgeons 
resulted in an adjusted study population of 177 surgeons. In addition, the study population included 75 
gastroenterologists and 75 anesthesiologists. As a result, the total targeted study population was 327 
physicians.   
Statistics 
Survey data were extracted into an Excel database. Statistical analyses were performed using SPSS 
(Version 21) and GraphPad Prism (Version 5). Analyses were performed using descriptive statistics.  
 
Results 
Participation 
As shown in table 1, a total of 192 physicians responded to the survey (response rate 58.7%), 
including 95 surgeons, 48 anesthesiologists and 49 gastroenterologists. Of 192 respondents, 158 
(82.2%) completed the survey, including 79 surgeons, 38 anesthesiologists and 41 
gastroenterologists. In total, in 73 of 75 hospitals (97.3%) one or more physicians responded to the 
survey. In 21 of 75 hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist, 
and a gastroenterologist. 
 
Preoperative blood management practice 
Regarding the use of red blood cell transfusions and the treatment of severe anemia, respondents 
from all hospitals indicated the perioperative use of a restrictive blood transfusion policy. According to 
the adapted 4-5-6 mmol/L hemoglobin transfusion trigger rule (Dutch transfusion guideline), the 
severity of anemia and the patient-specific cardiopulmonary compensation capacity was 
acknowledged.16 
 
To determine the current preoperative blood management practice per hospital, all respondents were 
first asked to indicate the primarily responsible specialist (gastroenterologist, surgeon, hematologist, 
anesthesiologist, unknown or none) for the management of mild to moderate preoperative anemia in 
colorectal cancer patients. Strikingly, in 33 of 44 hospitals with multiple respondents (minimum of two 
physicians per hospital), these responses differed and were contradictory, and needed reclassification: 
1. when per hospital multiple and different responses were given to the question who is primarily 
responsible for the treatment of mild to moderate anemia, the current preoperative blood management 
practice in the hospital was categorized as unclear/ambiguous.  
2. when per hospital multiple and different answers were given to the question whether iron 
parameters are measured during screening for colorectal cancer, the answer of the gastroenterologist 
was determinant.  
 
In twelve hospitals, an ongoing randomized clinical trial (FIT trial) during the survey period studied the 
efficacy of preoperative intravenous iron supplementation in comparison with preoperative oral 
supplementation in anemic patients with colorectal cancer.11 For these twelve hospitals, the content of 
the study protocol of the randomized trial was reflected in all answers regarding preoperative blood 
management practice. 
 
As shown in table 2, iron parameters (iron, ferritin, transferrin, or transferrin saturation) were indicated 
to be measured during screening for colorectal cancer in 38.7% of all hospitals. Of these 29 hospitals, 
complete iron status (iron, ferritin, transferrin, and transferrin saturation) was indicated to be measured 
in four hospitals.  In a total of 35 hospitals (46.7%), iron parameters were not measured during 
screening. In addition to the measurement of iron parameters during screening for colorectal cancer, in 
ten hospitals (13.3%) iron parameters were measured by the anesthesiologist at preoperative 
assessment, as compared to 37 hospitals (49.3%) in which iron parameters were not measured at 
preoperative assessment. In ten hospitals (13.3%), it was indicated that anemia observed at 
preoperative assessment, regardless of possible previous treatment by gastroenterologist or surgeon, 
was treated by the anesthesiologist, as compared to 34 hospitals (45.3%) in which this was not the 
case.  
 
Regarding the treatment of preoperative anemia, respondents from nineteen hospitals (25.3%), 
including the twelve hospitals participating in the ongoing FIT trial, indicated that the surgeons or colon 
care nurses were primarily responsible (table 2). In eleven hospitals (14.7%) the gastroenterologist 
was the first responsible to treat a mild to moderate preoperative anemia. In two hospitals each 
(2.7%), hematologists and anesthesiologists were indicated as primarily responsible for treatment, 
while in one hospital (1.3%) it was indicated that a mild to moderate preoperative anemia was not 
treated. In only four hospitals, the treatment of preoperative anemia was reported to be part of a 
protocol, with the aim of optimizing the preoperative condition of a patient. In half of the hospitals 
(49.3%), no clear policy regarding the treatment of preoperative anemia was reported. In 44 hospitals 
multiple responses (minimum of two physicians per hospital) to the question regarding the treatment of 
preoperative anemia were given, and in 33 hospitals (75.0%) these responses differed and were 
contradictory.  
 
Objectives for treatment of preoperative anemia  
All respondents were asked to prioritize their objectives for treatment of preoperative anemia. Results 
are shown in figure 1. Pooled responses demonstrated that, ‘prevention of blood transfusion, because 
of its association with impaired long-term tumor prognosis’ was ranked first, followed by ‘prevention of 
blood transfusion, because of its short-term side effects’, ‘prevention of preoperative anemia, because 
of its association with impaired long-term tumor prognosis’, ‘prevention of blood transfusion, because 
of its high expenses’, and ‘optimization of preoperative hemoglobin level for enhanced hemostasis’. 
This order of preference was similar for the different specialisms.   
 
Decision-making in treatment preoperative anemia 
Table 3 provides percentages of respondents considering different variables in their decision to treat 
preoperative anemia. Only respondents who had indicated to treat preoperative anemia themselves 
were asked this question. Overall, ‘age of patient’ was considered by 63.3% of all respondents, 
‘presence iron deficiency’ by 75.5%, ‘presence clinical symptoms of anemia’ by 85.7%, ‘presence of 
comorbidities’ by 83.7%, and ‘severity of anemia’ by 98.0%.  
 
In case respondents indicated  that their decision to treat anemia is dependent on the presence of iron 
deficiency, they were asked if the iron formulation (oral or intravenous) would depend on the type of 
iron deficiency (absolute versus functional iron deficiency), and if so, what treatment was chosen for 
an absolute and a functional iron deficiency anemia. Absolute iron deficiency is characterized by 
depleted iron stores (defined by decreased transferrin saturation and increased transferrin), while 
functional iron deficiency is caused by impaired iron homeostasis and is, due to increased hepcidin 
production, characterized by reduced iron uptake and iron mobilization from the reticulo-endothelial 
system (defined by decreased transferrin saturation and increased ferritin).  For a small minority of 
respondents (44.4%) the type of iron deficiency made a difference for their treatment. In case of an 
absolute iron deficiency anemia, intravenous iron was the first choice of treatment for 71.4% of these 
respondents (versus 28.6% oral iron ). In case of a functional iron deficiency, the choice of treatment 
was equally divided (50% oral iron versus 50% intravenous iron). 
 
Contraindications to intravenous iron therapy 
Figure 2 provides the percentages of respondents identifying different variables as an absolute 
contraindication to intravenous iron therapy. Overall, contraindications to intravenous iron therapy 
included ‘anemia not caused by iron deficiency’ for 65.8% of all respondents, ‘iron overload’ for 79.7%, 
‘hypersensitivity for intravenous iron’ for 86.1%, and ‘bacteremia’ for 15.2%. ‘Renal failure’ was 
indicated as an absolute contraindication by 15.2% of all respondents. Surgeons, gastroenterologists 
and anesthesiologists (78.5%, 92.1% and 95.1%, respectively) most frequently identified 
hypersensitivity for intravenous iron as absolute contraindication. Gastroenterologists and 
anesthesiologists (4.9% and 13.2%, respectively) least frequently indicated renal failure as absolute 
contraindication, while surgeons least frequently indicated bacteremia in this regard (7.6%). 
 
International guidelines on the long-term effects of iron therapy  
Overall, 8.9% of the respondents indicated to believe that the long-term oncological effects of 
intravenous iron therapy are known and already incorporated in the international guidelines on the 
treatment of anemia in cancer patients. 5.7% of the respondents indicated to regard intravenous iron 
as safe, while in contrast 3.2% of respondents believed intravenous iron therapy to be associated with 
impaired long-term tumor prognosis. 22.2% of the respondents indicated that the long-term 
oncological effects of intravenous iron therapy are not studied and therefore not included in the 
international guidelines. A vast majority (69%) indicated to be ignorant on this subject.  
 
Discussion 
The results of our national survey show a distinct variability in preoperative blood management 
practices in colorectal cancer patients. Strikingly, this variability is not only found among hospitals, but 
also within hospitals, demonstrated by variable responses from gastroenterologists, surgeons and 
anesthesiologists from the same institution. As a result, the present study clearly demonstrates the 
lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting in a 
suboptimal preoperative blood management strategy.  
Extensive research on barriers limiting the translation of PBM into clinical practice has led to simplified 
international recommendations for the implementation of PBM17-21. One of these recommendations is 
that each hospital should appoint a key leader for the PBM project management, who should have a 
central role in charge of communication, education, and documentation. This should contribute to a 
more clear division in responsibilities among treating physicians. Our study clearly demonstrates that 
this is not the case for the vast majority of Dutch hospitals. Most gastroenterologists, surgeons and 
anesthesiologists referred to different persons they held primarily responsible for the treatment of a 
mild to moderate preoperative anemia in colorectal cancer patients. In the few hospitals practicing 
preoperative blood management according to protocol, the primarily responsible persons were clear 
for all respondents.   
 
A second simplified recommendation is derived from the fact that effective correction of anemia will 
depend on the underlying disorder, and states that optimal PBM should involve screening for the 
underlying cause, preferably at the earliest opportunity to allow optimal correction.  With respect to this 
recommendation, our study again showed a high variation to which extent anemia and underlying 
causes were investigated and identified.  In only 38.7% of hospitals, iron parameters, essential for 
identifying type of anemia, were indicated to be measured during screening for colorectal cancer (by 
gastroenterologist or surgeon). In addition, in only 13.3% of hospitals, iron parameters were measured 
by the anesthesiologist during preoperative assessment. Most strikingly, anemia is, regardless of 
previous treatment by surgeon or gastroenterologists, treated by the anesthesiologist in only a quarter 
of the hospitals. These results clearly indicate that the majority of the Dutch hospitals are failing in the 
assessment and treatment of preoperative anemia. 
 
A third recommendation is that both physicians and nurses need to be trained in PBM clinical 
protocols and transfusion algorithms. According to our results, much progress could be made by 
improving the knowledge of physicians’ on these subjects. For example, in case of a functional iron 
deficiency, the choice of treatment was equally divided between oral and intravenous iron. This is a 
striking and counter-intuitive result, as oral iron is known to be nearly inefficacious in patients with a 
functional iron deficiency. In addition, the results of the acknowledgement of contraindications to 
intravenous iron emphasize the knowledge gap of the responding physicians. Renal failure, the 
commonest indication for intravenous iron therapy, was considered as an absolute contraindication by 
up to 15.2% of all respondents. Anemia not caused by iron deficiency and iron overload, which are 
clear contraindications to intravenous iron therapy, were indicated as such by only 66% and 80% of all 
respondents respectively. Hypersensitivity for intravenous iron is the most dangerous contraindication 
and acute hypersensitivity reactions during infusion are very rare but can be life-threatening. A review 
by Rampton et al. provides recommendations about their management and prevention.29 Importantly, 
if intravenous iron is to be given to individuals with any of the risk factors for acute hypersensitivity 
reactions (previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe 
atopy, systemic inflammatory diseases), an extremely slow infusion rate and meticulous observation is 
recommended. Finally, and notwithstanding the observed knowledge gap on PBM issues, possible 
long-term and potential hazardous effects of iron therapy in colorectal cancer patients are still unclear. 
Therefore, the long-term effects of iron therapy are not discussed in regard to the most optimal 
preoperative blood management strategy. Uncertainty on the potential role of iron in tumor progression 
arises from epidemiological and non-clinical studies, showing iron’s role in all aspects of cancer 
development and cancer growth.22-26 Despite the fact that the conditions in these epidemiological and 
non-clinical studies often not reflect the clinical situation in anemic patients and often use excessive 
iron doses iron-replete animals, we believe well-designed clinical studies are required to exclude the 
potential long-term hazardous effect of iron therapy in cancer patients.  
 
The increasing awareness to integrate PBM within routine surgical care, has resulted in numerous 
completed and ongoing trials studying the optimal blood management strategy in all types of 
surgery.11, 13, 27, 28 With regard to colorectal cancer, a pragmatic approach to the management of 
perioperative anemia is presented by Munoz et al.15 In this review, the use of PBM is strongly 
advocated to minimize or eliminate the use of allogeneic blood transfusion. Regarding the treatment of 
perioperative anemia, the use of oral iron is clearly dissuaded as it is poorly tolerated with low 
adherence based on published evidence, while the use of intravenous iron is strongly advised as it is 
safe and effective, but also frequently avoided due to misinformation and misinterpretation concerning 
the incidence and clinical nature of minor infusion reactions. In addition to this review and regarding 
the efficacy of intravenous iron therapy, a study by Keeler et al.12 showed that intravenous iron is more 
effective in increasing hemoglobin level compared to oral iron, but did not observe a relevant 
difference in the administration of red blood cell transfusions. However, in this trial the sample size 
was small and only primary outcomes in terms of increasing hemoglobin level and the use of red blood 
cell transfusions were reported, stressing the need for larger trials with a focus on functional 
performance and quality of life.11 The results of such trials should provide more evidence surrounding 
the effectiveness of the management of preoperative anemia, and should contribute to successful 
implementation of PBM protocols, specifically in colorectal cancer patients.   
 
Strengths and limitations 
The key strength of our study is the availability of responses from gastroenterologists, surgeons and 
anesthesiologists. This enables comparison between different medical disciplines within and between 
hospitals. Our data sets allows assessing the knowledge of the different types of physicians and 
assessing the consensus in the management of preoperative anemia.  In addition, in all hospitals 
except two, at least one physician responded to the survey. While the availability of responses from 
gastroenterologists, surgeons and anesthesiologists is a key strength of our study, it also appeared to 
be a limitation. Due to the high variety in responses, it was extremely difficult to determine the actual 
preoperative blood management strategy per hospital. An additional limitation of our study is that it is a 
national survey, hampering generalization of our results to an international setting. However, the 
Netherlands are known to be a pioneer in the implementation of PBM, using PBM strategies for more 
than two decades, especially for major orthopedic surgery.10 Therefore in other countries, physicians’ 
knowledge of blood management issues and implementation of PBM in colorectal cancer care will 
presumably not be superior to the Dutch setting. 
 
Conclusion 
The present study shows a distinct variability in preoperative blood management practices in 
colorectal cancer care. Strikingly, this variability which was not only seen among, but also within Dutch 
hospitals, was demonstrated by variable responses from gastroenterologists, surgeons and 
anesthesiologists from the same institution. As a result, the present study clearly demonstrates the 
lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting in a 
suboptimal preoperative blood management strategy. For a more effective and uniform 
implementation of PBM, much progress could be made on education as the present study clearly 
demonstrates a significant information deficit among physicians dealing with PBM issues. In addition, 
results of clinical trials providing evidence surrounding the effectiveness of treatment of preoperative 
anemia should contribute to more evidence-based guidelines. Finally, appointing key leaders for PBM 
project management should contribute to improved communication and cooperation, resulting in a 
more clear division in responsibilities among treating physicians.  
 
Figure 1. Objective treatment preoperative anemia 
Figure 2. Respondents opinions on contraindications for intravenous iron 
 
Table 1. Characteristics/distribution respondents  
  
  n  %  
Responses per specialism  
  
   Surgeons (177 invited in total) 95 53.7 
   Gastroenterologists (75 invited in total) 49 65.3 
   Anesthesiologists (75 invited in total) 48 64.0 
 
  
Responses per hospital (75 in total) 
  
   Surgeon(s) 8 10.7 
   Gastroenterologist 4 5.3 
   Anesthesiologist 9 12.0 
   Surgeon(s) + gastroenterologist  14 18.7 
   Surgeon(s) + anesthesiologist 12 16.0 
   Gastroenterologist + anesthesiologist 5 6.7 
   Surgeon(s) + gastroenterologist + anesthesiologist  21 28.0 
   No response 2 2.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Current practices for preoperative blood management in all centers (n=75), according to respondents  
  n % 
Iron parameters measured during screening colorectal cancer 
  Answered by: gastroenterologists and surgeons 
     Yes 29 38.7 
   No 35 46.7 
   Unknown/missing 11 14.7 
   Treatment of anemia first started by 
  Answered by: gastroenterologists, surgeons and anesthesiologists 
     Gastroentrologist 11 14.7 
   Surgeon 15 20.0 
   Colon care nurse 4 5.3 
   Hematologist/internist 2 2.7 
   Anesthesiologist 2 2.7 
   Unclear/ambiguous policy 37 49.3 
   No treatment 1 1.3 
   Unknown/missing 3 4.0 
   Iron parameters measured at preoperative assessment anesthesiology 
  Answered by: anesthesiologists 
     Yes 8 10.7 
   No 37 49.3 
   Unknown/missing 30 40.0 
   Treatment of anemia by anesthesiologists, regardless of previous treatment 
  Answered by: anesthesiologists 
     Yes 10 13.3 
   No 34 45.3 
   Unknown/missing 31 41.3 
 
Table 3. Decision making in treatment preoperative anemia 
  
  
  
Gastroenterologists, n 
(%) 
Surgeons, n 
(%)  
Anesthesiologists, n 
(%)  
Total, n 
(%) 
A. Variables considered in decision making treatment preoperative anemia  
 
     Age of patient 16 (76.2) 12 (66.7) 3 (30) 31 (63.3) 
   Presence iron deficiency 19 (90.5) 13 (72.2) 5 (50) 37 (75.5) 
   Presence clinical symptoms anemia 20 (95.2) 14 (77.8) 8 (80) 42 (85.7) 
   Presence comorbidities 18 (85.7) 15 (83.3) 8 (80) 41 (83.7) 
   Severity of anemia 21 (100) 17 (94.4) 10 (100) 48 (98) 
 
  
  B. Type of treatment (oral or intravenous iron) is dependent on type of iron deficiency (absolute versus functional iron deficiency) 
 
   Yes 3 (30) 4 (66.7) 1 (50) 8 (44.4) 
   No 7 (70) 2 (33.3) 1 (50) 10 (55.6) 
 
  
  C. First choice of treatment in case of an absolute iron deficiency anemia 
 
     Oral iron              0 (0) 2 (50) 0 (0) 2 (28.6) 
   Intravenous iron  3 (100) 2 (50) 0 (0) 5 (71.4) 
 
  
  D. First choice of treatment in case of a functional iron deficiency anemia 
 
     Oral iron 1 (33.3) 2 (66.7) 0 (0) 3 (50) 
   Intravenous iron 2 (66.7) 1 (33.3) 0 (0) 3 (50)  
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